Cargando…

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China

Baseline and on-treatment characteristics, including age, obesity, calcium intake, and bone turnover markers, may predict the bone mineral density (BMD) response in women with postmenopausal osteoporosis (PMO) to 1 to 2 years of antiresorptive therapy and/or vitamin D supplementation. This study aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Er-Yuan, Zhang, Zhen-Lin, Xia, Wei-Bo, Lin, Hua, Cheng, Qun, Wang, Li, Hao, Yong-Qiang, Chen, De-Cai, Tang, Hai, Peng, Yong-De, You, Li, He, Liang, Hu, Zhao-Heng, Song, Chun-Li, Wei, Fang, Wang, Jue, Zhang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081166/
https://www.ncbi.nlm.nih.gov/pubmed/30075569
http://dx.doi.org/10.1097/MD.0000000000011694
_version_ 1783345616480370688
author Liao, Er-Yuan
Zhang, Zhen-Lin
Xia, Wei-Bo
Lin, Hua
Cheng, Qun
Wang, Li
Hao, Yong-Qiang
Chen, De-Cai
Tang, Hai
Peng, Yong-De
You, Li
He, Liang
Hu, Zhao-Heng
Song, Chun-Li
Wei, Fang
Wang, Jue
Zhang, Lei
author_facet Liao, Er-Yuan
Zhang, Zhen-Lin
Xia, Wei-Bo
Lin, Hua
Cheng, Qun
Wang, Li
Hao, Yong-Qiang
Chen, De-Cai
Tang, Hai
Peng, Yong-De
You, Li
He, Liang
Hu, Zhao-Heng
Song, Chun-Li
Wei, Fang
Wang, Jue
Zhang, Lei
author_sort Liao, Er-Yuan
collection PubMed
description Baseline and on-treatment characteristics, including age, obesity, calcium intake, and bone turnover markers, may predict the bone mineral density (BMD) response in women with postmenopausal osteoporosis (PMO) to 1 to 2 years of antiresorptive therapy and/or vitamin D supplementation. This study aimed to explore clinical characteristics associated with 12-month BMD improvement in Chinese women with postmenopausal osteoporosis (PMO). In this post hoc analysis of a previous phase 3 multicenter, randomized controlled trial, Chinese PMO women who were treated with once weekly alendronate 70 mg/vitamin D3 5600 IU (ALN/D5600) or once daily calcitriol 0.25 mcg, and had measurements of 1-year lumbar spine BMD (LS-BMD) and on-treatment bone turnover markers (BTMs) were included in the analysis. In Chinese PMO patients on ALN/D5600, 1-year LS-BMD change was negatively correlated with age (β = −0.00084, P < .01), dietary calcium (β = −0.0017, P = .07), and procollagen type 1 N-terminal propeptide (P1NP) change at month 6 (β = −0.000469, P = .0016), but positively with body mass index (BMI) (β = 0.00128, P = .08); baseline P1NP above the median was associated with a significantly greater BMD percentage change at the lumbar spine (P = .02) and the total hip (P = .0001). In the calcitriol group, a significant 1-year LS-BMD increase was associated with BMI (β = 0.0023, P = .02), baseline P1NP (β = 0.00035, P = .0067), history of prior vertebral fracture(s) (β = 0.034, P < .0001) and baseline serum 25(OH)D level (β = −0.00083, P = .02). The presented findings from Chinese postmenopausal osteoporotic women suggested clinically meaningful baseline and on-treatment characteristics predicting BMD improvement after 1 year of ALN/D5600 treatment, which differed from calcitriol treatment with baseline identifiable associations. The study remained exploratory and further accumulation of evidence is needed.
format Online
Article
Text
id pubmed-6081166
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-60811662018-08-17 Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China Liao, Er-Yuan Zhang, Zhen-Lin Xia, Wei-Bo Lin, Hua Cheng, Qun Wang, Li Hao, Yong-Qiang Chen, De-Cai Tang, Hai Peng, Yong-De You, Li He, Liang Hu, Zhao-Heng Song, Chun-Li Wei, Fang Wang, Jue Zhang, Lei Medicine (Baltimore) Research Article Baseline and on-treatment characteristics, including age, obesity, calcium intake, and bone turnover markers, may predict the bone mineral density (BMD) response in women with postmenopausal osteoporosis (PMO) to 1 to 2 years of antiresorptive therapy and/or vitamin D supplementation. This study aimed to explore clinical characteristics associated with 12-month BMD improvement in Chinese women with postmenopausal osteoporosis (PMO). In this post hoc analysis of a previous phase 3 multicenter, randomized controlled trial, Chinese PMO women who were treated with once weekly alendronate 70 mg/vitamin D3 5600 IU (ALN/D5600) or once daily calcitriol 0.25 mcg, and had measurements of 1-year lumbar spine BMD (LS-BMD) and on-treatment bone turnover markers (BTMs) were included in the analysis. In Chinese PMO patients on ALN/D5600, 1-year LS-BMD change was negatively correlated with age (β = −0.00084, P < .01), dietary calcium (β = −0.0017, P = .07), and procollagen type 1 N-terminal propeptide (P1NP) change at month 6 (β = −0.000469, P = .0016), but positively with body mass index (BMI) (β = 0.00128, P = .08); baseline P1NP above the median was associated with a significantly greater BMD percentage change at the lumbar spine (P = .02) and the total hip (P = .0001). In the calcitriol group, a significant 1-year LS-BMD increase was associated with BMI (β = 0.0023, P = .02), baseline P1NP (β = 0.00035, P = .0067), history of prior vertebral fracture(s) (β = 0.034, P < .0001) and baseline serum 25(OH)D level (β = −0.00083, P = .02). The presented findings from Chinese postmenopausal osteoporotic women suggested clinically meaningful baseline and on-treatment characteristics predicting BMD improvement after 1 year of ALN/D5600 treatment, which differed from calcitriol treatment with baseline identifiable associations. The study remained exploratory and further accumulation of evidence is needed. Wolters Kluwer Health 2018-08-03 /pmc/articles/PMC6081166/ /pubmed/30075569 http://dx.doi.org/10.1097/MD.0000000000011694 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Liao, Er-Yuan
Zhang, Zhen-Lin
Xia, Wei-Bo
Lin, Hua
Cheng, Qun
Wang, Li
Hao, Yong-Qiang
Chen, De-Cai
Tang, Hai
Peng, Yong-De
You, Li
He, Liang
Hu, Zhao-Heng
Song, Chun-Li
Wei, Fang
Wang, Jue
Zhang, Lei
Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China
title Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China
title_full Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China
title_fullStr Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China
title_full_unstemmed Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China
title_short Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China
title_sort clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d(3) or calcitriol treatment: exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in china
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081166/
https://www.ncbi.nlm.nih.gov/pubmed/30075569
http://dx.doi.org/10.1097/MD.0000000000011694
work_keys_str_mv AT liaoeryuan clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT zhangzhenlin clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT xiaweibo clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT linhua clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT chengqun clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT wangli clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT haoyongqiang clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT chendecai clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT tanghai clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT pengyongde clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT youli clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT heliang clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT huzhaoheng clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT songchunli clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT weifang clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT wangjue clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina
AT zhanglei clinicalcharacteristicsassociatedwithbonemineraldensityimprovementafter1yearalendronatevitamind3orcalcitrioltreatmentexploratoryresultsfromaphase3randomizedcontrolledtrialonpostmenopausalosteoporoticwomeninchina